IMF Publication - Understanding Ninlaro®(ixazomib) capsules
IMF Publication - Understanding Ninlaro®(ixazomib) capsules
Ninlaro® (ixazomib) is the first oral proteasome inhibitor approved by the FDA to treat myeloma. Ninlaro is the third drug in the proteasome inhibitor class that has been approved for myeloma. It is indicated for myeloma patients who have received at least one prior therapy. You can also download a copy here: https://www.myeloma.org/resource-library/understanding-ninlaro |
-
Shipping Information
FREE SHIPPING for all tip cards and publications.
Shipping times typically take 7-14 business days. Orders totaling up to $49.99 will incur a shipping cost of $5; orders totaling $50 and up will incur a shipping cost of $10.
Currently, the IMF does not provide international shipping via our Shopify store. If you are planning to purchase IMF merchandise or to order free educational publications outside of the U.S. (including U.S. territories), please contact the IMF directly at the imf@myeloma.org or 1-818-487-7455.